Major Volatility Seen In BioCryst (BCRX) Shares
More News related to BCRX
- BioCryst Pharma (BCRX) Priced 5M Common Offering at $9.75/Share
- BioCryst Announces Pricing of Public Offering of Common Stock
- Momentum Mover BioCryst (BCRX) Down On Stock Offering
- BioCryst Pharma (BCRX) Files 5M Common Stock Shelf
- BioCryst Announces Proposed Public Offering of Common Stock
More News related to Insiders' Blog
- Provident Financial (PROV) Commences $40M Stock Offering
- QKL Stores (QKLS) Completes 6 Million Share Offering
- Microvision (MVIS) Prices 3.3M Shares at $3/Share for Net Proceeds of ~$9.3M
- Yongye Int'l (YONG) Files $100M Mixed Securities Shelf
- SINA Corp. (SINA) Completes $180M Private Equity Financing with New-Wave
Investors are betting on wild action in BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), which hopes at this time are pinned on flu drug peramivir for swine flu.
Recently BioCryst received orders from the U.S. for 10,000 courses of intravenous peramivir for H1N1 after the company was granted emergency use authorization from the FDA after a request by the CDC.
According to option strategists at Susquehanna, during morning trading investors in BioCryst got long both the March 10 calls and December 20 puts, roughly 2,000 times each. On this the firm said "it is likely that these investors are positioning for higher levels of volatility in shares of BCRX."
Currently peramivir is authorized only for hospitalized adult and pediatric patients for whom therapy with an i.v. drug is clinically appropriate, based on one or more of the following reasons:
1. the patient is not responding to either oral or inhaled anti-viral therapy, or
2. when drug delivery by a route other than an intravenous route -- e.g., enteral (absorbed by the intestines) or inhaled -- is not expected to be dependable or feasible;
3. for adults only, when the clinician judges i.v. therapy is appropriate due to other circumstances.
There have been stories so far of great success with peramivir in H1NI, but bears note that the government also has orders for intravenous versions of Tamiflu and Relenza, which are much cheaper than peramivir. Bears suggest once the swine flu hype is over, gains will disappear.
Wall Street coverage is pretty scant on the stock. Only five analysts cover the stock. One rates it a Buy, three rate it a Hold and one rates it a Sell.
Shares of BioCryst are up 2.6 percent today to $12.10.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-0.51Related Entities
Comments
instant cure by peramivir
Something is missing from the story: the reason that Israel is buying lots of this drug is because 5 days ago a paitient with swine flu that was given everything else that didnt work and was very close to death was given the Peramivir and recovered immidiately and fully. When I saw it on the news the first thing I did is buy this stock. I am certain that if the same happens in other countries the stories will reach international exposure and the price of the share will go way over $20.
phantom drugs
IV for tamilfu and relenza are not available. The HHS order is predicated on clinical trials and scientific evidence before they get approved. Considering these aren't even in or passed a PH I trial exactly how quickly do you expect these drugs to get approved for an EUA? Biocryst is the ONLY company that has an approved IV drug: Peramivir and they DELIVERED what was ordered by the HHS and so far have seen 90% positive results. Please put some details into your story instead of making a FLUFF HIT PIECE.
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
instant cure by peramivir
romema on Nov 14, 2009 02:11 PMSomething is missing from the story: the reason that Israel is buying lots of this drug is because 5 days ago a paitient with swine flu that was given everything else that didnt work and was very close to death was given the Peramivir and recovered immidiately and fully. When I saw it on the news the first thing I did is buy this stock. I am certain that if the same happens in other countries the stories will reach international exposure and the price of the share will go way over $20.